Professional Documents
Culture Documents
Terminologa
CINV: Chemotherapy-induced nausea and vomiting. Nausea y vmito inducidos por QMT.
HEC: Highly emetogenic chemotherapy. QMT altamente emetgena. MEC: Moderately emetogenic chemotherapy. QMT moderadamente emetgena. AR 5-HT3: Antagonistas de los receptores de serotonina.
Quimioterapia
Mucositis Diarrea Nausea Vmito Mielosupresin
CINV
Factores de riesgo:
Joven Mujer Historial de poca ingesta de alcohol Emesis durante el embarazo Calidad de vida deteriorada Experiencia previa con QMT
Fisiopatologa de la Emesis
Chemoreceptor trigger zone:
Serotonina (5-HT3) Sustancia P (NK-1) Dopamina (D2)
ASCO 2011
MASCC/ESMO 2010
La guas de la NCCN, MASCC (Multinational Association Of Supportive Care In Cancer) y la ASCO recomiendan administrar aprepitant para la prevencin de la nausea y vmito tarda cuando se administran esquemas AC (doxorrubicinaCFM).
Bibliografa
Basch, E. (2011). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. Geling, O. ; Eichler, HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 h after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:128994. Guzman, Flavio. (2009). Serotonin 5-HT3-receptor antagonists: pharmacokinetics, MOA, indications and adverse effects (Disponible en: http://pharmacologycorner.com/serotonin-5-ht3-receptor-antagonists. Consultado el: 17/05/2012). Jordan, K. (2007). Comparative activity of antiemetic drugs. Critical Reviews in Oncology/Hematology, 61:162175. Machu, Tina. (2011). Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions. Pharmacology & Therapeutics, 130, 338347. NCCN GuidelinesTM. (2012). NCCN Clinical Practice Guidelines in Oncology; Antiemesis. (Disponible en: Consultado el: 19/05/2012). Oliver, I. (2005). Update on anti-emetics for chemotherapy-induced emesis. Internal Medicine Journal,35:478481.
Bibliografa
Roila, F. ; Herrstedt, J. ; Aapro, M. (2010).Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of Oncology, 21: 232243. Rojas, C. (2010). Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. European Journal of Pharmacology, 26:193199. Rojas, C. ; Slusher, B. (2012). Pharmacological mechanisms of 5-HT3 and Tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. European Journal of Pharmacology, 684:17. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10:115. Sharma, R. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol, 6: 93102. UpToDate, Inc. (2012). Prevention and treatment of chemotherapy-induced nausea and vomiting. (Disponible en: www.uptodate.com/contents/prevention-and-treatmentof-chemotherapy-induced-nausea-and-vomitiing. Consultado el: 17/5/2012).